{"id":"NCT00963469","sponsor":"Organon and Co","briefTitle":"Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)","officialTitle":"A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-08","primaryCompletion":"2001-11","completion":"2001-11","firstPosted":"2009-08-21","resultsPosted":"2010-06-09","lastUpdate":"2022-02-03"},"enrollment":1079,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"montelukast sodium","otherNames":[]},{"type":"DRUG","name":"Comparator: loratadine","otherNames":[]},{"type":"DRUG","name":"Comparator: placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to evaluate the treatment effect of montelukast 10 mg taken in the morning, versus placebo, in patients with seasonal allergic rhinitis. Loratadine is included in the study as an active control.","primaryOutcome":{"measure":"Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment Period","timeFrame":"Baseline and first 2 Weeks of treatment period (from randomization through the end of Week 2)","effectByArm":[{"arm":"Placebo","deltaMin":-0.23,"sd":null},{"arm":"Montelukast","deltaMin":-0.33,"sd":null},{"arm":"Loratadine","deltaMin":-0.45,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["14616102"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":451},"commonTop":["Headache"]}}